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Abstract
Identifying biomarkers for tuberculosis (TB) is an ongoing challenge in developing immuno-
logical correlates of infection outcome and protection. Biomarker discovery is also neces-
sary for aiding design and testing of new treatments and vaccines. To effectively predict
biomarkers for infection progression in any disease, including TB, large amounts of experi-
mental data are required to reach statistical power and make accurate predictions. We took
a two-pronged approach using both experimental and computational modeling to address
this problem. We first collected 200 blood samples over a 2- year period from 28 non-
human primates (NHP) infected with a low dose ofMycobacterium tuberculosis. We identi-
fied T cells and the cytokines that they were producing (single and multiple) from each sam-
ple along with monkey status and infection progression data. Machine learning techniques
were used to interrogate the experimental NHP datasets without identifying any potential
TB biomarker. In parallel, we used our extensive novel NHP datasets to build and calibrate
a multi-organ computational model that combines what is occurring at the site of infection
(e.g., lung) at a single granuloma scale with blood level readouts that can be tracked in mon-
keys and humans. We then generated a large in silico repository of in silico granulomas
coupled to lymph node and blood dynamics and developed an in silico tool to scale granu-
loma level results to a full host scale to identify what best predictsMycobacterium tubercu-
losis (Mtb) infection outcomes. The analysis of in silico blood measures identifiesMtb-
specific frequencies of effector T cell phenotypes at various time points post infection as
promising indicators of infection outcome. We emphasize that pairing wetlab and computa-
tional approaches holds great promise to accelerate TB biomarker discovery.
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Author Summary
Tuberculosis (TB) is a disease that is caused by infection after inhaling the bacterium
Mycobacterium tuberculosis. Not everyone infected with TB bacteria becomes sick. As a
result, two TB-related conditions have been categorized: latent TB infection (not sick but
still harboring the bacteria) and active TB disease. If not treated properly, active TB disease
can be fatal. Almost 1.3 million die of TB worldwide each year, with ~8,6 million new
infections in 2013. No effective vaccine is available to protect against TB and treatment of
infection with multiple antibiotics is lengthy (6–9 months), with non-compliance being a
major factor for the emergence of drug-resistant strains. A key step in developing effective
vaccines and possibly shorter treatment regimens is the ability to identify biomarkers that
correlate prognosis and progression to infection (similar to how cholesterol levels are a
measure of heart health). In this study we show how pairing computer modeling, statistics
and mathematics with datasets derived from non-human primate studies can accelerate
biomarker discovery, and offer a new approach to identifying correlates of protection that
will be useful in clinical practice, particularly in developing countries where TB is most
prevalent.
Introduction
Mycobacterium tuberculosis (Mtb) continues to be a global public health threat, responsible for
1.3 million deaths due to tuberculosis (TB) and 8.6 million new infections in 2013 [1]. While
only 10% of infected individuals develop clinically active TB, the other 90% harbor bacteria
and are considered to be clinically latent [2] (latent TB, or LTBI). Clinically latent individuals
can undergo reactivation to active TB, and thus serve as a large reservoir for disease transmis-
sion. A major hurdle in controlling TB is the lack of accurate biomarkers that correlate progno-
sis and progression to infection [3,4,5,6].
Identification of biomarkers for both infectious and non-infectious diseases is a focus of
much current biomedical research. While blood or urine can be obtained from patients to mea-
sure biomarkers, events occurring in these physiological compartments may not accurately
reflect dynamics at sites of infection, such as lungs [7]. We recently showed that during Mtb
infection, T cell responses in blood do not consistently reflect T cell responses within granulo-
mas, sites of Mtb infection in lungs [8]. Biomarkers associated with the observed spectrum of
infection, ranging from control of infection (LTBI) to clinically active TB [9], are unknown.
This lack of understanding is present in settings of both natural and vaccine-induced immunity
[6]. Here we focus our study in a natural immunity setting.
Non-specific markers of inflammation, when considered alone, do not have sufficient pre-
dictive value for clinical use in TB [3,4]. For decades, the Tuberculin Skin Test (TST) has been
the most common diagnostic tool for Mtb exposure. However, lack of specificity for detection
of active TB disease, inability to distinguish between BCG vaccination and Mtb infection, and
inability to provide insight into disease progression limit the predictive power of TST [3,4,5].
IFN-γ Release Assays (IGRA), which measure Mtb-specific release of IFN-γ from blood cells,
have higher specificity for detection an ongoing TB infection (~80%) [10] but fail both as a use-
ful correlate of vaccine-induced protection and a reliable predictor of disease progression (i.e.,
due to low sensitivity or true positive rate) [3,4]. Recent association studies suggest that ratios
of various T cell subpopulations in blood (e.g., CD4+ vs CD8+ T cells) may help distinguish
among stages of TB progression [2,11,12,13]. Time course data in humans are typically only
available from blood, and not from sites of Mtb infection (lungs or lymph nodes (LNs). In
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addition, it is challenging to determine the time of exposure and infection progression status in
humans, limiting the ability to use these samples for predictive studies.
Gene expression profiling [2,14,15], microRNA and metabolism-based discovery [16,17],
and plasma antibody profiling in Mtb infected humans [18] and animal models [3,19] have
been paired with data mining and machine learning tools to uncover potential TB biomarkers.
Imaging has been recently used successfully as a diagnostic and prognostic tool in TB studies
(i.e., PET/CT scan), both in the context of natural infection [20,21] and drug-treatment
[22,23]. While informative, these studies have thus far been unable to determine either a single
or suite of practical biomarkers, or predictive correlates of protection that would be useful in
clinical practice, particularly in developing countries where TB is most prevalent. This is likely
due to the complexity of TB disease, that blood may not reflect lung infection dynamics [8],
intrinsic limitations in ex vivo studies and limited availability of longitudinal in vivo data.
Moreover, a spectrum of infection outcomes overlying binary classifications of active TB and
latent infection has been identified, making biomarker discovery for infection status even more
challenging [9].
Here we present an integrated experimental and computational modeling approach toward
the discovery of TB biomarkers with the goal of predicting Mtb infection outcomes. Fig 1
shows a methodology roadmap of the different datasets generated and analyses performed in
this study. First, using machine learning, immunologic data from blood of Mtb-infected cyno-
molgus macaques was interrogated for biomarkers that would predict infection outcome. The
analysis of the NHP blood datasets did not identify any potential TB biomarker. A separate
dataset was then used to help build and calibrate a computational model of the immune
response during Mtb infection. Our unique multi-scale and multi-physiological compartmen-
tal computational model generates in silico data on dynamics of infection in both blood and
lung, capturing formation of independent granulomas in lungs and at the same time T cell pro-
files in blood. We then constructed virtual non-human primate hosts based on granuloma data
and infection status from macaques, and used these models to identify potential biomarkers
that can predict infection outcome. We found that Mtb-specific frequencies of effector T cell
phenotypes (i.e., both CD4+ and CD8+) in the blood can be targeted to distinguish infection
outcomes, with a clear separation between median trajectories of active versus latent TB late
during infection progression (~300 days).
Results
To help the readers navigate through the many datasets generated and the different analyses
performed in this study, we provide a detailed methodology roadmap (Fig 1). Each step labeled
in Fig 1 refers to a section in the Results, with emphasis on the order in which they have been
performed.
A range of classification algorithms fails to reveal markers of disease
outcome in a novel non-human primate dataset
We assessed levels of CD4+ and CD8+ T cells (and memory subsets based on the expression of
the two markers CD45RA and CD27, see Table 1 for details) and their cytokine production in
the blood of 28 non-human primates (NHPs) (cynomologus macaques) at 10 time points over
the course of experimental Mtb infection (up to 6 months post infection) (Fig 2A, Table 1, S1–
S6 Tables). Such an extensive time course of sampling in the NHP model of TB, which recapit-
ulates human Mtb infection, has not been previously available for biomarker studies. These
NHPs were clinically classified as having either latent infection or active TB disease as previ-
ously described [24,25], but exhibit a range of outcomes encompassing these clinical
Systems Biology Approach to Biomarker Discovery in TB Infection
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Fig 1. Methodology roadmap. The left side of the diagram (gray boxes) summarizes all of the datasets generated in this study. We have generated
experimental datasets from blood samples and lung necropsies of non-human primates (NHPs), and datasets generated by computational model simulations
(in silico data). The right side of the diagram (yellow boxes) represents the analyses performed on each dataset. Each dataset is displayed by a different
shape. The blue arrows point to the type of analysis performed on each dataset. The circled numbers represent the chronological order of operations
(referred to as steps in the text). Details on which Fig or table in the manuscript contain a dataset or analysis are given in each box.
doi:10.1371/journal.pcbi.1004804.g001
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classifications [26]. S1 Fig shows representative flow cytometry plots outlining gating strategies
employed in assessing T cell levels.
To interrogate these unique and extensive NHP infection datasets for biomarkers (step 1 in Fig
1), we applied four supervised classification algorithms: classical and penalized discriminant analy-
sis (LDA and PLDA), quadratic discriminant analysis (QDA) and logistic regression (full details
are given in the Methods and Supplemental materials). Sensitivity, specificity and misclassification
error rates (MER) are shown in Table 2 for both training and test sets. Results of the training data-
set show high accuracy, even if overfitting is likely driving it (since we have 28 samples for more
than 150 features). However, similar results were not observed in the test data set, where none of
the four methods used was able to discriminate disease outcomes (MERs for the test set ~50%,
Table 1. Summary of the NHP experimental machine learning, computational model calibration and scaling-to-host predictions.
Dataset Supplementary
Tables
# of animals
(NHPs)
Days sampled Data Collected Data Used For
NHP classiﬁcation+CFU/
gran data (Lung)
S1 Table 43(20 Active
TB, 23
Latent TB)
One time point
at necropsy
• NHP ID
• Outcome classiﬁcation
• Time of necropsy (days)
• Number of granulomas
• CFU/gran data
• Model Calibration
(lung)
• Scaling to host
Single Cytokine dataset
(Blood)
S2 Table 28(14 Active
TB, 14
Latent TB)
0, 10, 20, 30,
42, 56, 90, 120,
150 and180
Single Cytokines on CD4+ and CD8+ T
cells levels
1. CD4 markers (8): GMCSF , IFNγ , IL-2 ,
IL-10 , TNF, IL-17, IL-6, IL-4
2. CD8 markers (9): CD-107 , GMCSF ,
IFNγ , IL-2 , IL-10 , TNF, IL-17, IL-6, IL-4
• Supervised and
Unsupervised
Classiﬁcation
• Features =8x10
+9x10=170
Multiple Cytokine
dataset (Blood)
S3 Table 19(10 Active
TB, 9 Latent
TB)
10, 20, 30, 42,
56, 90, 120,
150 and 180
Multiple Cytokines on CD4+ and CD8+ T
cells levels
1. CD4 markers (5): GMCSF , IFNγ , IL-2 ,
IL-10 , TNF
2. CD8 markers (6): CD-107 , GMCSF ,
IFNγ , IL-2 , IL10 , TNF
• Supervised and
Unsupervised
Classiﬁcation
• Features = 5x9
+6x9=99
Memory Single
Cytokines dataset
(Blood)
S4 Table 28(14 Active
TB, 14
Latent TB)
0, 10, 20, 30,
42, 56, 90, 120,
150 and 180
Single Cytokines on CD4+ and CD8+ T
cells phenotypes (Naïve-N [CD45RA
+ CD27+], Effector-E or Terminally
Differentiated-TD [CD45RA+CD27-], Central
Memory-CM [CD45RA-CD27+] and Effector
Memory-EM [CD45RA-CD27-])
1. CD4 markers (8): GMCSF , IFNγ , IL-2 ,
IL-10 , TNF, IL-17, IL-6, IL-4
2. CD8 markers (9): CD-107 , GMCSF ,
IFNγ , IL-2 , IL-10 , TNF, IL-17, IL-6, IL-4
• Supervised and
Unsupervised
Classiﬁcation
• Features = 8x10
+9x10=170
T Cell dataset (Blood) S5 Table 9 0 10, 20, 30,
42, 56, 90, 140,
and 167
CD4+ and CD8+ T cell phenotypes
Naïve-N [CD45RA+ CD27+], Effector-E or
Terminally Differentiated-TD [CD45RA
+CD27-], Central Memory-CM
[CD45RA-CD27+] and Effector Memory-EM
[CD45RA-CD27-]
• Model Calibration
(blood)
ESAT-6 + CFP-10 or
ESAT-6 & CFP-10
Memory T cell dataset
(Blood)
S6 Table 28 0, 10, 20, 30,
42, 56, 90, 120,
150 and 180
All CD4+ and CD8+ T cell phenotypes
producing any CK in response to
stimulation to ESAT6 or CFP10
Naïve-N [CD45RA+ CD27+], Effector-E or
Terminally Differentiated-TD [CD45RA
+CD27-], Central Memory-CM
[CD45RA-CD27+] and Effector Memory-EM
[CD45RA-CD27-]
• Model Validation
(blood)
doi:10.1371/journal.pcbi.1004804.t001
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Table 2; S2 Fig). The stark differences in predictive accuracy between the training and test datasets
indicate over-fitting, which could potentially be mitigated by increasing sample size.
We next re-analyzed the blood datasets using unsupervised clustering algorithms (multidi-
mensional scaling, Ward’s method and other hierarchical methods, see Materials and Methods
for full details). These algorithms suggested that the 28 macaques can be subdivided into 3–25
optimal clusters (S7 Table), but there was no agreement among the methods in terms of what
the clustering should be. The clusters contain mixtures of NHPs with active disease and latent
infection, with no clear separation between subjects and no distinct delineator of infection
stage. This is likely due to the overlapping spectrum of pathology present in animals that are
clinically classified as having active disease or latent infection [8,9,21,22,25], as also described
for humans [27]. Overall, our multiple attempts to use longitudinal blood T cell data obtained
from NHPs to predict the clinical binary classification (i.e. latent infection or active TB) were
not successful.
Computational model recapitulates blood NHP data on both T cell levels
and their cytokine production
Our NHP blood dataset may not be predictive of infection outcomes if blood does not reflect
lung infection dynamics (as suggested by our previous work [8]) and/or if the sample size does
not have the necessary statistical power to discriminate binary outcomes. In addition, TB exists
on a spectrum and identifying binary outcomes may be an artificially imposed constraint and
not practical [9]. These shortfalls could be mitigated using a computational model that
describes the immune response to Mtb infection in three physiological compartments captur-
ing blood, LNs and lung dynamics, calibrated with our NHP datasets (step 2 in Fig 1 and Fig
2B). Building on previous work from our group, we developed a multiscale and multicompart-
ment model by linking our computational model GranSim that captures individual granuloma
formation and function in the lungs using an agent-based model framework
[28,29,30,31,32,33] with 2 additional non-linear ODE models capturing dynamics in both LN
and blood [28,29] (Fig 2, S1 Text).
Figs 3 and 4 illustrate the calibration of our in silicomodel to our NHP dataset, with both
spatial and temporal fits to distinct data from individual granulomas in lungs (Fig 3) and blood
(Fig 4) (ranges for parameter values given in S8 and S9 Tables). In addition, bacterial burden
per granuloma (in colony forming units, CFU) in the lung are calibrated to recently published
[8,22] and unpublished NHP datasets (Fig 3A, S1 Table). Time courses for the number of Mtb
bacteria from a representative contained granuloma are shown in Fig 3B. We also show a com-
parison between granuloma spatial distribution (e.g., location of immune cells, bacteria,
necrotic center) from two NHP granuloma images and two in silico granuloma snapshots with
similar Mtb bacteria levels and lesion size (Fig 3C). NHP T cell dynamics (S5 Table) from 9
animals were used to calibrate our in silico blood dynamics, and in silico trajectories fall within
the levels of the CD4+ and CD8+ T cells from NHP blood (Fig 4).
Fig 2. Experimental design and computational model. (A) Experimental design for data collection and measurement on the 28 Non-Human Primate. All
the datasets are available online as Supporting Information (S2–S6 Tables). (B) Schematic representing the three compartments captured by our
computational model. The emphasis is on describing all the lymphocyte phenotypes (both CD4+ and CD8+) tracked during the analysis. The cells populate
three different compartments/organs: lung, lymph node and blood. The lung is modeled as an Agent-Based Model (ABM), while the blood and the lymph
node are modeled as an Equation-Based Model (EBM), namely as an Ordinary Differential Equation (ODE) system. For most of the phenotypes, both Mtb-
specific (colored) and non Mtb-specific (grey) cells are tracked. APC: represented as a proxy in the computational model (see Materials and Methods section
and S1 and S2 Texts for details).
doi:10.1371/journal.pcbi.1004804.g002
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Fig 3. Computational model calibration: LUNG.NHP experimental data on CFU/granuloma (S1 Table) are plotted here versus the in silico datasets of
CFU/granuloma (lung compartment) from in silico repository of 10,000 granulomas coupled to the blood and LN dynamics). Although the in silico dataset has
time courses up to 600 days, the x-axis always shows a time span of infection up to 200 days to match the NHP blood data. The y-axis represents CFU/
granuloma (A-B). (A) In silico dataset of time courses of CFU/granuloma generated in the lung compartment (black circles, with the black solid line
representing the median trajectory) compared to experimental data on NHP CFU/granuloma (with the solid red line representing the median, and the dotted
red lines representing the min and max values in the NHP data). The median trajectories for both the NHP and in silico data are calculated including the
Systems Biology Approach to Biomarker Discovery in TB Infection
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Computational model allows for prediction of dynamics of Mtb-specific
T cells
Currently, Mtb-specificity of T cells in the NHP model cannot be directly measured (for exam-
ple, tetramers are not available). As a surrogate, we used our NHP blood dataset to calculate
frequency of T cells that produce any of 6 cytokines measured (IFN-γ IL-2, IL-6, IL-10, IL-17
and TNF) (S6 Table) following stimulation with two Mtb-specific immunodominant antigens
ESAT-6 and CFP-10 (S6 Table). These T cell frequencies are then used as proxies for the fre-
quencies of Mtb-specific T cells (at least from the perspective of a functional response to these
antigens). This does not provide a direct measure of cells that are truly Mtb-infection specific.
The NHP used in this study are outbred monkeys that could have been exposed to non-tuber-
culous mycobacteria (NTMs, or environmental exposure) and would nonetheless respond to
stimulation with these antigens prior to our infecting them with Mtb. This may explain the
non-zero frequencies in the NHP dataset present in many of the memory T cell phenotypes
observed early during infection (red dots, Fig 5). The computational model does not account
for these potential effects.
We next used our calibrated in silicomodel to predict the spatio-temporal dynamics of
Mtb-specific T cells (see Materials and Methods section for details). To parallel our computa-
tional model of virtual NHPs that would also previously be exposed to mycobacterial antigens,
our simulations start with non-zero initial conditions in the same frequencies as the NHP data.
Our in silicomodel predictions for frequencies of Mtb-specific Central Memory (Fig 5A and
5C) and Effector T cells (Fig 5B and 5D) are within the variation of the NHP data that derived
as proxies for Mtb-specific T cell responses.
In silico frequencies of Mtb-specific Effector CD4+ and CD8+ T cells in
blood correlate to CFU per granuloma in the lung
We next apply data mining techniques and correlation methods on these in silico datasets for
discovery of potential biomarkers (step 4 in Fig 1). Since our computational model can predict
dynamics of Mtb-specific cells in blood, lung and LNs, we use our model to generate large in
silico datasets (10,000 virtual granuloma), pairing lung outputs (i.e., CFU/granuloma dynam-
ics) with blood measures (immune cell dynamics) over the time course of infection (step 3 in
Fig 1). We first apply principal component analyses (PCA) to the in silico blood readouts only
(S3 Fig), and then we extend the analysis to the 3 compartment readouts combined together
(e.g., blood, lymph node and single granuloma in the lung, see S11 Table and S4 and S5 Figs). If
the analysis is performed only on Mtb-specific T cell variables in the blood, the top 2 principal
components alone explain ~70% of dataset variability (S3A Fig). Even if no cluster emerges
(S3B Fig), the top 2 principal components are dominated by Mtb-specific effector CD4+ and
effector CD8+ T cells, as early as 42 days post infection, as well as Mtb-specific Central Mem-
ory CD4+ and CD8+ T cells later during infection (S3C Fig). To explore this finding further,
we narrowed the analysis of the in silico datasets by correlating virtual Mtb-specific frequencies
of T-cells in blood to virtual CFU/granuloma at the site of infection (lungs). In silico
sterilized granulomas, while the min trajectories excluded the sterilized granulomas. (B) Mtb trajectories (total [solid thick], extracellular [solid with empty
circles], intracellular [dotted] and non-replicating [solid thin]) in a representative granuloma (containment) compared to the NHP CFU/granuloma
experimental data (red circles). (C) Snapshots of 4 different granulomas. The top row of Panel C is for H and E staining of two NHP granulomas. The left
granuloma is from NHP 22810, CFU~40. The right granuloma is from NHP 17211, CFU~1240. Both granulomas are ~ 2mm in diameter (see S1 Table for
details). The bottom row of Panel C is for in silico granulomas, matching lesion size and CFU/granuloma of the NHP images. Cell types displayed are the
following: macrophages (resting-green, activated-blue, infected-orange, chronically infected-red), effector lymphocytes (pro-inflammatory IFN-γ producing T
cells-Tγ in pink, cytotoxic T cell-Tc in purple, regulatory T cell-Treg in light blue), extracellular bacteria (olive green), vascular sources (grey and necrotic spots
(white)).
doi:10.1371/journal.pcbi.1004804.g003
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Fig 4. Computational model calibration to NHP data from blood. NHP experimental data on blood T cell phenotypes (S5 Table, T cell dataset) are plotted
here versus the in silico datasets of blood T cell phenotypes (blood compartment), from in silico repository of 10,000 granulomas coupled to the blood and LN
dynamics. Although the in silico dataset has time courses up to 600 days, the x-axis always shows a time span of infection up to 200 days to match the NHP
blood data. The y-axis represents cells/cm3. (A-H) In silico dataset of 10,000 time courses of 8 T cell phenotypes generated in the blood compartment (black
solid line [mean] and black dashed lines [5th and 95th percentiles]) compared to experimental data on T cell phenotypes in the blood of Mtb-infected NHPs
(red dashed lines with red open circles, representing the min and max). For the minimum and maximum of the NHP data we chose the lowest and highest
values at any time point across all the NHPs. In silico predictions are displayed as median (black solid line) and minimum and maximum (dashed black lines).
We show Naïve CD4+ ((A) and CD8+ (E)), Central Memory CD4+ (B) and CD8+ (F)), Effector CD4+ (C) and CD8+ (G)) and Effector Memory CD4+ (D) and
CD8+ (H). The in silico data have been obtained by summing the respective Mtb-specific and non Mtb-specific equations of the blood compartment of the
computational model.
doi:10.1371/journal.pcbi.1004804.g004
Fig 5. Model validation of in silicoMtb-specific frequencies. Trajectories over 200 days of T cell frequencies from the computational model against NHP
experimental data. The in silico data have been generated following steps illustrated in Fig 6, as well as in the Materials and Methods section. Given the non-
zero frequencies in the pre-infection stages, we used initial conditions between 0.01% and 2% for the Mtb-specific Central and Effector memory phenotypes.
The red dots represent NHP experimental data, namely the frequencies of T cells producing any of the 6 cytokine measured (IFN-γ, IL-2, IL-6, IL-10, IL-17
and TNF) in response to ESAT-6 and CFP-10 stimulation (see Materials and Methods section for details and S6 Table for the data). Only 9 NHPs data are
plotted here. The black solid (mean) and dashed (5th and 95th percentiles) lines represent the trajectories of the in silico data. Panel A: Frequencies of CD4
+ T cell Central Memory phenotypes. Panel B: Frequencies of CD4+ T cell Effector Memory phenotypes (Terminally Differentiated and Effector Memory).
Panel C: Frequencies of CD8+ T cell Central Memory phenotypes. Panel D: Frequencies of CD4+ T cell Effector Memory phenotypes (Terminally
Differentiated and Effector Memory).
doi:10.1371/journal.pcbi.1004804.g005
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frequencies of Mtb-specific Effector CD4+ and CD8+ T cells in blood predict well the granu-
loma-scale bacterial burden, with a clear separation between low vs high CFU/granuloma (all
results shown in supplement at the granuloma scale- S6 and S7 Figs, S10 Table). However,
since infection usually results in multiple granulomas within a single host, a host scale-readout,
not a single granuloma-scale readout, would be more useful. We provide such an analysis
below.
In silico frequencies of Mtb-specific Effector CD4+ and CD8+ T cells in
blood predict host infection outcomes
We next generate host-scale predictions by combining NHP lung necropsy data and the in sil-
ico repository described in the previous section (Fig 1, step 5). Our main assumption is that
host-scale clinical outcomes can be determined by the combined effect of a host’s heteroge-
neous granuloma bacterial burden [21]. In fact, we previously demonstrated substantial hetero-
geneity and variability in NHP granulomas at the bacterial and immune cell levels, both among
animals and within a single animal [8,21,22]. Total bacterial burden in NHP lungs at necropsy
correlates with infection outcome (i.e. NHP with active disease have higher bacterial burden
than those with latent infection) [25]. The contribution of individual (and total) granulomas in
a single host to factors that can be tracked in blood is not clear, and likely is responsible for the
lack of correlation of T cell responses in blood with those in granulomas or with clinical status
in our previous study [8].
Fig 6. Scaling to host methodology. Experimental data on 43 Mtb-infected NHPs classified as either latent or active TB will be used to guide virtual NHP
building process (see Materials and Methods section for further details). Step 1.One NHP out of the 43 (NHPi, i = 1, . . .,43) is selected and the number of
granulomas (Ni) to sample from the in silico repository is determined, together with the CFU per each granuloma (CFUj, j = 1,. . ..,Ni). Step 2. For each CFUj,
we select a subset of in silico granulomas from the repository within the range [(1-α)xCFUj, (1+α)xCFUj]. We used α = 10%. The subset is sampled at the
time point necropsy for NHPi was performed (see details on S1 Table). Step 3. Statistics on blood readouts are calculated (i.e., mean, median, standard
deviation) and stored. Step 4. Steps 1–3 are repeatedK times for the same NHPi to mimic the variability and heterogeneity in granuloma outcomes within a
single host. TheK replications are then stored and host-scale statistics are computed (i.e., mean, median, standard deviation) and combined to simulate
trajectories of in silico blood readouts to predict infection outcomes, as shown in Fig 7.
doi:10.1371/journal.pcbi.1004804.g006
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To scale our computational model results from single lung granuloma to whole host, we
first generate a large sample of virtual NHP hosts by using our in silico dataset to simulate
NHP infections (Fig 6) that recapitulate known CFU/granuloma data (S1 Table). We generated
virtual hosts that contained the number of granulomas and CFU/granuloma to match our
NHP dataset (step 5 in Fig 1). For each virtual NHP host, we sample from our in silico reposi-
tory of 10,000 granulomas (see Materials and Methods section for detail). We then combine all
the sampled in silico granulomas and examine their corresponding in silico blood data on
immune cell levels as generated from the computational model. This technique allows us to
predict time courses of many different T cell phenotypes in the blood using our computational
model (step 6 in Fig 1). Our goal here is to predict the collective behavior of latent and active
TB groups rather than in silico blood trajectories of single NHP. Thus the scaling to host analy-
sis does not include the computation of specificity, sensitivity and misclassification rates.
Predicted numbers of CD4+ and CD8+ T cells (including the subsets of Mtb-specific T
cells) in blood were generated for 43 virtual NHP (20 latent infection, 23 active TB as in the
experimental NHP dataset) (Fig 7 and S8 and S9 Figs). These predictions match the NHP
blood dataset, suggesting that one cannot distinguish between active and latent TB outcomes
by monitoring total T cell levels (Fig 7A–7C and S8A and S8C–S8E Fig).
Fig 7. Scaling to host infection outcome predictions for Mtb-specific T cell frequencies.We built/calibrated virtual NHPs that replicate granuloma
heterogeneity and variability in the lung of 43 NHPs (up to 600 days post infection, see S1 Table). Here, in silico blood trajectories of total T cell levels and
Mtb-specific T cell frequencies grouped by clinical outcome (as shown in S1 Table) are plotted over 600 days for the same set of virtual NHPs. The in silico
data shown here have been generated following steps illustrated in Fig 6, as well as in Materials and Methods section. The two virtual trajectories
representing the 43 virtual NHPs are displayed in all the panels as mean +/- 2x(standard error). The asterisks show significant (p<0.05) student t-test
between the two trajectories at the same time point. These in silico trajectories have been generated with zero initial conditions for the Mtb-specific T cell
memory phenotypes (except for Naïve Mtb-specific T cells, see Materials and Methods section for details). No experimental data is shown here since blood
measures are only available for a limited number of NHPs (I.e., 12 out o 43) and only up to 180 days post infection. Panel A: Total CD4+ T cell levels. Panel B:
Total CD8+ T cell levels. Panel C: Total Mtb-specific CD4+ T cell levels. Panel D: Total Mtb-specific CD8+ T cell levels. Panels E: Mtb-specific frequencies of
Effector CD4+ T cells. Panels F: Mtb-specific frequencies of Effector Memory CD4+ T cells. Panels G: Mtb-specific frequencies of Effector CD8+ T cells.
Panels H: Mtb-specific frequencies of Effector Memory CD8+ T cells.
doi:10.1371/journal.pcbi.1004804.g007
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In contrast, predicted Mtb-specific T cell levels in blood do allow us to distinguish infection
outcomes (active vs latent) by ~300 days post infection (both CD4+ and CD8+, Fig 7C and 7D).
The predicted frequencies of Mtb-specific Effector CD4+ and CD8+ T cells in virtual active vs
latent hosts separate after 300 days post infection (Fig 7E and 7G). The predicted frequencies of
Mtb-specific Effector Memory CD4+ and CD8+ T cells are also indicative of outcome but at later
time points (Fig 7F and 7H). Overall, we predict that frequencies of Mtb-specific effector CD4
+ and CD8+ T cells in blood are significantly higher (from 2- to 4- fold) in an active versus a
latent Mtb-infected NHP and thus a combination of these cells and various time points post-
infection should be targeted as potential biomarkers of Mtb infection progression.
Discussion
One of the greatest tools in disease diagnosis and treatment is a robust biomarker. In TB, there
been has much debate regarding whether biomarkers exist and, if so, what could serve as
appropriate biomarkers [3,4,5,10,11,12,13,14,15,16,17,18,19,34,35]. To date, no biomarker (or
set of biomarkers) has been shown to be useful in discriminating the extent of infection and
disease in humans. One of the complications in predicting Mtb infection status is the spectrum
of disease outcomes encompassed within the binary classifications of active TB and latent
infection [9,36,37]. This variability in disease outcome is also paralleled by heterogeneity in
granuloma outcomes both between, and within, individual NHPs.
We previously reported that a spectrum of granulomas, in terms of numbers, types, immune
responses and bacterial burden are found in individual animals and among animals with active
or latent infection [8,22,25]. Recent studies from our group support that progressive and healed
granulomas can coexist within the same animal, with nearly all animals capable of sterilizing at
least a subset of individual granulomas [21]. However, animals with active TB show a subset of
lesions that do not control infection, which presumably results in dissemination [22]. Not sur-
prisingly, given this heterogeneity within hosts, systemic T cell responses in the blood do not
accurately reflect granuloma T cell responses [8].
Here we collected a unique and extensive set of phenotypic and functional T cell data in
blood from 28 NHPs experimentally infected with a low dose of Mtb and with a known clinical
outcome (active or latent TB). We present an approach that integrates these experimental
NHP data into a computational model capturing immune dynamics in 3 physiological com-
partments. We apply classical data mining techniques to temporal datasets from blood that are
derived from both NHP studies and from our computational model. A major benefit of using
data mining techniques on computational data is that in silico datasets are exhaustive in both
time and density, allowing for greater sample sizes and statistical power. This can rule out
small sample size as a potential error in the corresponding animal study and point to other fac-
tors at play. Standard supervised and unsupervised classification algorithms returned no clear
decomposition or optimal cluster distribution. This suggested that the resolution of NHP
blood measures that were collected was not able to identify potential biomarkers of disease pro-
gression, possibly due to the overlap between the binary classifications of infection outcome.
Moreover, if we speculate that clinical outcome of hosts can ultimately be driven by the com-
bined activity of an individual’s granuloma burden, sampling the blood will likely reflect the
average dynamics of variable local immune responses to infection. Ultimately, we were unable
to identify biomarkers from NHP experimental data collected in a systemic compartment
(blood), indicating the complex nature of localized lung disease in TB.
To offer complementary analyses, we built a novel and unique multi-organ computational
model that tracks infection dynamics in lungs, blood and LNs, using the extensive NHP datasets
distinctly for model building, calibration and validation. This allows generation of a large (on the
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order of thousands) parallel in silico dataset to mine for potential biomarkers. One aspect of our in
silico system is the ability to accurately simulate Mtb-specific T cell frequencies over time. These
data indicate that Mtb-specific effector CD4+ and CD8+ T cell frequencies in the blood could serve
as potential biomarkers to predict infection outcome. Although full ranges of Mtb-specific T cell
frequencies are not currently measurable in primates, many studies are now available onMtb pro-
tein epitopes (e.g., ESAT-6, Ag85B, 16kDa, 19kDa, Hsp65, Rv1490) for the most common human
HLAs (reviewed in [38]). For each epitope, ranges for frequencies of antigenic-specific T cells span
from 0.05% up to 1–2%. If we assume that an entire Mtb-specific frequency repertoire can be repre-
sented by the sum of the responses to many of these epitopes, our new scaling-to-host methodology
offers predictions that are quantitatively comparable to these ranges (Fig 7 and S8 Fig).
Because of the variability in human HLA molecules and the large number of potential Mtb
antigens, distinguishing total Mtb-specific T cell frequencies in blood is not yet feasible, espe-
cially for CD8+ T cells. However, recent studies have identified novel epitope sequences from
Mtb that may soon be targets to discriminate and quantify Mtb-specific T cell responses
[38,39]. This will allow prediction of infection status or treatment outcome using peripheral
blood samples from infected hosts [40,41,42,43,44,45]. For example, a recent study by Sette
et al [39] provides an extensive list of Mtb-derived epitopes recognized by CD4+ T cells from
healthy and LTBI individuals. The authors emphasize how CD4+ T cells from both groups rec-
ognize non-tuberculous mycobacteria (NTMs, or environmental exposure) epitopes (likely
from previous exposure). This might also explain the large variability identified in the NHP T
cell data derived herein (Fig 5). The list of peptides that reflect true Mtb-specific versus envi-
ronmental responses is by no means complete, but we can reasonably speculate that more
Mtb-specific epitopes will be identified in the near future. By measuring these pathogen-spe-
cific responses, we will have a more adequate estimate of Mtb-specific immunity generated
upon infection to correlate with protection or outcomes. Moreover, by including these combi-
nations of Mtb-specific epitopes into our computational model, we could eventually predict
infection outcome earlier or discriminate among a spectrum of infection outcomes.
A recent study on MDR-TB patients shows how our approach can be viable in a clinical set-
ting. Riou et al [40] identified a subset of activated and proliferating Mtb-specific CD4+ T cells
(i.e., Ki67+ HLA-DR+) as a potential marker in peripheral blood that predicts the time to spu-
tum culture conversion in TB patients at the start of treatment. Another recent prospective
proof-of-concept study uses a novel T-cell activation marker-tuberculosis (i.e., TAM-TB) assay
on cryopreserved peripheral blood mononuclear cell samples to diagnose active TB in children
based on ratios of CD27 phenotype of CD4 T cells producing IFNγ in response to Mtb antigens
(i.e., ESAT6 and CFP10) [42].
It has been also suggested that a shift of Mtb-specific Central Memory to Mtb-specific Effec-
tor Memory CD4+ T cells precedes the clinical diagnosis of active TB by many months [44]. If
we restrict our analysis to ratios of Mtb-specific Effector Memory to Mtb-specific Central
Memory T cell frequencies (in silico data), no significant difference can be shown between
latent and active TB infection groups (see S9A Fig). However, our in silico predictions for the
time courses of the ratios of Mtb-specific Effector to Mtb-specific Central Memory CD4+ T
cells, and higher ratios in the active TB group (statistically significant only after day 300 post
infection) confirm the finding of Schuetz et al (S9B Fig and [44]).
In complex diseases such as heart disease and cancer, a suite of biomarkers best predicts dis-
ease outcomes and treatment intervention points. Our studies support that for TB, a complex
lifelong infection that is compartmentalized primarily in the lung, single biomarkers in blood
may not be a feasible goal. Coupled to the idea that infection outcome in hosts likely occurs
over a spectrum, identification of a single biomarker may be a misguided goal. Our novel sys-
tems biology approach combined with the ongoing progress to elucidate and winnow down
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Mtb-specific epitopes can significantly influence hypothesis generation for biomarker predic-
tion for TB. Any in silico prediction can then be validated on human clinical data and animal
model studies, adding important knowledge to human immunity to TB and TB intervention
studies.
Materials and Methods
Study design
The goal of this study was to develop a methodology to identify biomarkers for TB infection
outcome. Our systems biology approach integrates non-human primate (NHP) datasets
together with computational modeling, allowing the generation of virtual hosts that we use for
biomarker discovery. The next sections illustrate: i) the experimental datasets, ii) classification
algorithms, iii) computational modeling framework, iv) in silico datasets analysis, v) model cal-
ibration and vi) virtual hosts generation. Refer to Fig 1 for a general roadmap of all the different
datasets that have been generated and all the many analysis that have been performed in this
study.
Ethics statement
All experimental manipulations, protocols, and care of the animals were approved by the Uni-
versity of Pittsburgh School of Medicine Institutional Animal Care and Use Committee
(IACUC). The protocol assurance number for our IACUC is A3187-01. Our specific protocol
approval numbers for this project are 11090030 and 12060181. The IACUC adheres to national
guidelines established in the Animal Welfare Act (7 U.S.C. Sections 2131–2159) and the Guide
for the Care and Use of Laboratory Animals (8th Edition) as mandated by the U.S. Public
Health Service Policy.
All macaques used in this study were housed at the University of Pittsburgh in rooms with
autonomously controlled temperature, humidity, and lighting. Animals were singly housed in
caging at least 2 square meters that allowed visual and tactile contact with neighboring conspe-
cifics. The macaques were fed twice daily with biscuits formulated for non human primates,
supplemented at least 4 days/week with large pieces of fresh fruits or vegetables. Animals had
access to water ad libitem. Because our macaques were singly housed due to the infectious
nature of these studies, an enhanced enrichment plan was designed and overseen by our non-
human primate enrichment specialist. This plan has three components. First, species-specific
behaviors are encouraged. All animals have access to toys and other manipulata, some of
which will be filled with food treats (e.g. frozen fruit, peanut butter, etc.). These are rotated on
a regular basis. Puzzle feeders foraging boards, and cardboard tubes containing small food
items also are placed in the cage to stimulate foraging behaviors. Adjustable mirrors accessible
to the animals stimulate interaction between animals. Second, routine interaction between
humans and macaques are encouraged. These interactions occur daily and consist mainly of
small food objects offered as enrichment and adhere to established safety protocols. Animal care-
takers are encouraged to interact with the animals (by talking or with facial expressions) while
performing tasks in the housing area. Routine procedures (e.g. feeding, cage cleaning, etc) are
done on a strict schedule to allow the animals to acclimate to a routine daily schedule. Third, all
macaques are provided with a variety of visual and auditory stimulation. Housing areas contain
either radios or TV/video equipment that play cartoons or other formats designed for children
for at least 3 hours each day. The videos and radios are rotated between animal rooms so that the
same enrichment is not played repetitively for the same group of animals.
All animals are checked at least twice daily to assess appetite, attitude, activity level, hydra-
tion status, etc. FollowingM. tuberculosis infection, the animals are monitored closely for
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evidence of disease (e.g., anorexia, weight loss, tachypnea, dyspnea, coughing). Physical exams,
including weights, are performed on a regular basis. Animals are sedated prior to all veterinary
procedures (e.g. blood draws, etc.) using ketamine or other approved drugs. Regular PET/CT
imaging is conducted on most of our macaques following infection and has proved very useful
for monitoring disease progression. Our veterinary technicians monitor animals especially
closely for any signs of pain or distress. If any are noted, appropriate supportive care (e.g. die-
tary supplementation, rehydration) and clinical treatments (analgesics) are given. Any animal
considered to have advanced disease or intractable pain or distress from any cause is sedated
with ketamine and then humanely euthanatized using sodium pentobarbital.
Experimental datasets
Twenty-eight cynomolgus macaques (Macacca fasicularis) were infected with a low dose of
Mtb (Erdman strain, ~25–50 CFU) and monitored clinically for signs and symptoms of TB up
to six months post infection. Infection was confirmed by tuberculin skin test conversion and/
or lymphocyte proliferation assay six weeks post-infection. The macaques were classified (as
previously described in [22,23,25]) to have either clinically latent TB infection or active TB (S1
Table, third column) based on clinical, radiological and microbiologic criteria. Peripheral
blood was collected at time-points: pre Mtb infection (only for 9 NHPs) and at days 10, 20, 30,
42, 56, 90 (or M3, 3 months), 120 (or M4), 150 (or M5) and 180 (or M6) post infection. PBMC
were isolated, stimulated with peptide pools of Mtb specific antigens ESAT-6 and CFP-10
(10μg/ml of each peptide) or phorbol dibutyrate (PDBu) and ionomycin as positive control
and media as negative control, in the presence of Brefaldin A (BD biosciences) for 6 hours at
37°C with 5%CO2. Multi-parametric intracellular flow cytometry was performed on fresh
PBMC to assess CD4 and CD8 T cell cytokine profiles (GMCSF (clone: M5D12), IFN-γ (B27),
IL-2(MQ1-17H12), IL-4 (8D4-8) IL-6 (MQ2-6A3), IL-10 (JES3-9D7), IL-17(64CAP17) and
TNF (MA611)) during the course of Mtb infection. S1 Fig shows representative flow cytometry
plots where we outline our gating strategies employed in the analysis of T cells in PBMC.
We generated four different datasets: a single cytokine dataset (where each cell was labeled
for a single cytokine, S2 Table), amultiple cytokine dataset (where each cell was labeled for the
simultaneous presence of more than 1 cytokine, S3 Table), amemory single cytokine dataset (S4
Table, where the same cytokines profile of the single cytokine dataset is stratified by CD4+ and
CD8+ memory sub-populations based on the expression of CD45RA and CD27, namely
Naïve-N [CD45RA+ CD27+], Central Memory-CM [CD45RA-CD27+], Effector Memory-EM
[CD45RA-CD27-] and Terminally Differentiated-TD or Effector-E [CD45RA+CD27-] and a
T cell dataset (where only CD4+ and CD8+ memory phenotypes levels are measured, S5
Table). S6 Table summarizes the frequencies of ESAT6 or CFP10-stimulated memory T cells
that produced any cytokine (i.e., IFN-γ, IL-2, IL-6, IL-10, IL-17 and TNF) upon stimulation.
All these datasets are displayed in Fig 1 under the grey box labeled NHP data, with a detailed
description given in Table 1. The complete datasets are available as supplementary material
(S1–S6 Tables). The experimental design is described in Fig 2A. The time points measured in
the T cell dataset (S5 Table) differ slightly from the other three datasets (S2–S4 Tables, see
Table 1 for details on the four datasets). The first three datasets were used for machine learning
(step 1 in Fig 1), while the T cell dataset (S5 Table) was used to build (Fig 2B) and calibrate the
in silicomodel for the blood compartment of the computational model ((step 2 in Fig 1 and Fig
4). Moreover, the ESAT6-CFP10 Memory T cell dataset (S6 Table) was used for a tentative
model validation of the Mtb-specific frequency predictions of our in silicomodel (Fig 5). S1
Table describes on all the NHPs enrolled in the study. A total of 58 NHPs have been monitored
(all have been classified as either latent [green] or active [red] TB), 28 of which have
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immunologic data from blood (single,multiple and memory cytokine datasets, as well as T cell
dataset). As for the number of granulomas and CFU per granuloma data, S1 Table has all the
details on the 43 NHPs that have been necropsied (with time of necropsy included), 12 of
which are included in the 28 NHPs of the blood data. S1 Table was used to calibrate the lung
compartment of the computational model (step 2 in Fig 1 and Fig 3).
Data preparation for data mining
The data for some cytokine profiles was imputed (ascribed) using the techniques described in
[46], which relies on a “nearest neighbor” or local averaging approach to fill in missing values.
The imputation approach is stochastic in nature [46], and hence is sensitive to an initial ran-
dom seed. The results presented below were obtained by averaging over 1000 trials of imputing
and classifying. The results were qualitatively unchanged regardless of whether cytokine pro-
files were scaled to have unit variance. The analysis was performed in R (version R 2.14.2) and
in Matlab ((R2011b v7.13)).
Supervised classification algorithms
In order to identify possible correlates of protection on the experimental data in S2–S4 Tables,
we applied two types of classification techniques, discriminant analysis and logistic regression
[47]. The most popular versions of these techniques rely on a linear relationship (i.e., linear dis-
criminant analysis-LDA) between the correlates of protection and TB infection outcome of the
macaques. Due to the relatively poor performance of these classical approaches, we also applied
three other techniques that feature additional flexibility. The first is quadratic discriminant
analysis (QDA), which can be appropriate if quadratic relationships exist between possible cor-
relates and the TB infection outcome [47]. The last two techniques utilize a statistical tech-
nique, termed l1 regularization, that relies on constrained optimization to identify important
variables in the model and hence minimize the misclassification error rate of the different mod-
els[47]. We refer to the last two models as penalized linear discriminant analysis (PLDA) and
logistic regression. The cross-validation functions within the R package are used to select the
regularization parameters for PLDA and logistic regression [48,49]. In addition to performing
all techniques on the data sets, we also applied each technique to the data projected onto the
first 3 principal components, which captured over 50% of variability in the data. Our goal in
doing this was to try to improve performance by reducing the number of cytokine covariates.
Our goal is to predict TB infection outcome, a binary variable (1 for active; 0 for latent) and
performances for the different methods are measured with a set of special metrics called sensi-
tivity, specificity and misclassification error. Sensitivity is the rate at which active TB infections
are correctly predicted (true positive rate), specificity is the rate at which latent TB infections
are correctly predicted (true negative rate), and misclassification error rate is the overall predic-
tion error rate [48]. To avoid reporting overly optimistic (biased due to over-fitting) results, we
withhold 50% of the data when estimating the model parameters and test the fitted model on
the withheld data. Henceforth, we refer to the withheld data as test data and the rest of the data
used to estimate the model as training data. Results are qualitatively unchanged for a different
number of macaques in the test dataset vs training set. Note also that data are considered by
each of the four techniques to be cross-sectional, i.e., direct application of each method ignores
temporal information.
Unsupervised classification algorithms
Since we found that six macaques in the study were consistently incorrectly classified by our
classification algorithms, we re-analyzed the blood data using unsupervised clustering
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algorithms (i.e., multidimensional scaling, Ward’s method and other hierarchical methods,
and k-means)[47]. These algorithms attempt to find inherent groupings in the cytokine pro-
files, and hence could potentially identify a possible spectrum of latency rather than delineating
between active and latent cases.
Multidimensional scaling (MDS) is a visualization technique that forms a two-dimensional
representation of the macaques, where the location of each macaque in two-dimensional space
is optimized so that macaques close together are most similar.
Complete and Average link hierarchical clustering, as well as Ward’s method are called
“agglomerative” or bottom-up approaches, because they start with each macaque as its own
cluster and then cluster them together until a stopping criteria is met. In contrast to agglomera-
tive approaches, K-means is a top-down partitioning method, where initially all macaques
belong to a single cluster. The clusters are then progressively split into smaller clusters
(reviewed in [47]). One would expect to find consistent results between these different tech-
niques, even though they take varying approaches to discovering macaque groupings. Wildly
varying results across methods would indicate that the data feature high levels of noise that
mask a possible structure between macaques.
Computational model
Our hybrid agent-based model (ABM, labeled GranSim) tracks Mtb infection in 3 physiological
compartments: lung (site of infection), draining lymph node (LN, site of generation of adaptive
immunity) and blood (a measurable compartment, see Fig 2B for details). Our computational
model captures single granuloma formation and function in the lung [30,31,32,33], while LN
and blood compartments[28,29] represent dynamics of the whole body in response to infec-
tion. We simulate infection over a time span of 600 days, with rules and interactions solved on
a 10 min time step which can be found at http://malthus.micro.med.umich.edu/GranSim/.
The lung environment represents a 2x2 mm section of lung parenchyma tissue. Details on
lung initialization can be found in [30,31,32]. Cell types captured in the model are macro-
phages and T cells (or T lymphocytes). Macrophages transition between the following states:
resting, activated, infected and chronically infected. T cells are represented by their functions:
Tγ (i.e., IFNγ-producing T cells, necessary for macrophage activation), Tcyt (i.e., cytotoxic T
cells) and Treg (regulatory T cells). Two effector molecules are also tracked, namely tumor
necrosis factor-α (TNF) and interleukin 10 (IL-10).
LN and blood dynamics are each captured by compartmentalized system of ordinary differ-
ential equations (ODEs) (see S1 Text for the equations and derivation). We updated our pub-
lished multi-compartment computational models34, 35, in which we now track CD4+ and CD8
+ T lymphocytes with different memory phenotypes (i.e., Naïve, Effector, Central and Effector
Memory).
Two mechanisms new to GranSim are used herein: T cell recruitment and proliferation at
the site of infection (described in detail in S2 Text—T cell recruitment and T cell proliferation
in the lung).
Lymph node and blood compartment
A great advantage of the in silico representation is that we can track both Mtb-specific and non
Mtb-specific T cells (the T cell dataset does not discriminate between Mtb-specific and non-
Mtb-specific cell types). The lymph node-blood dynamics are captured by 31 ODE equations
with 21 independent parameters. Measure units are cell counts in the LN and cell/mm3 in
blood. Details on the initial conditions of the model as well as parameter ranges are given in S8
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and S9 Tables. Fig 2B illustrates the different T lymphocyte phenotypes tracked in the model
and some assumptions regarding cell priming, trafficking and differentiation.
Our experimental data show that a single LN drains multiple granulomas forming in lungs
[20,21,22]. We coarse-grain cell migration from the site of infection (GranSim) to a draining
lymph node. Antigen presentation and priming occurring in LNs is driven by a proxy for anti-
gen presenting cell dynamics (APCs, Eqn (1.1) in S1 Text), which is the count of macrophages
in the lung that interacted with Mtb (MMtb) at any time during infection (see [28] for details on
the implementation). However, only a small fraction of cells (e.g., ~5–10%) that encounter Mtb
in lungs is thought to be able to traffic and migrate to LNs [50,51,52,53,54]. Due to computa-
tional limitation, the lung compartment tracks formation and progression of a single granu-
loma and not multiple granulomas developing simultaneously. Thus, the MMtb count is an
overestimate for the APC trafficking to the LN from a single granuloma. However, we use the
MMtb count as a reasonable proxy for APC dynamics for the whole host. This assumption
implies that we are calibrating the computational model as if the host is developing between 10
and 20 similar granulomas in the lungs (matching the ~5–10% cells that likely migrate to the
LN upon infection) [25]. This allows us to use the T cell dataset to calibrate the computational
model in the blood (since the blood data measured in that dataset reflect TB infection of a
whole NHP), as well as in the lung by using our data on CFU per granuloma in NHPs [21,22].
Based on the above assumptions, when multiple granulomas are combined together to generate
virtual NHPs and capture heterogenous granuloma outcomes within a single host, the in silico
blood readouts for the whole host are computed as averages and medians (instead of sums)
across all the granulomas sampled (see Figs 6 and 7 and S8 and S9 Figs). We are currently
working on a computational platform where multiple granulomas can be simulated simulta-
neously and have potential to interact with each other, mimicking a whole lung infection
dynamics.
Two T-cell phenotypes traffic between LN and blood, namely naïve and central memory
cells (separate equations are described for CD4+ and CD8+ T cells, as well as for Mtb-specific
and non-Mtb-specific, see S1 Text for details). Mtb-specific naïve T cells are primed by APCs
in LNs to become precursor T cells, which proliferate and ultimately differentiate into Mtb-
specific Central Memory and/or Mtb-specific Effector, depending on the strength of APC stim-
ulation [55,56,57,58]. Mtb-specific Central Memory cells can be re-stimulated in LNs (similarly
to Naïve) and become precursor again [59,60]. Mtb-specific Effector cells can differentiate into
Mtb-specific Effector Memory cells [61]. All cells in the LN compartment (except APC and
precursor) migrate into blood (as shown in Fig 2B).
We modeled Mtb-specific CD4+ T cell processes in the LN and blood compartments identi-
cal to how CD8+ T cells are modeled, with the exception of Mtb-specific Naïve CD8+ priming
which is dependent of Mtb-specific Naïve CD4+ priming. We modeled non-Mtb-specific T
cells (grey circles in Fig 2B) similarly to their respective Mtb-specific cell types (colored circles
in Fig 2B) counter parts. However, non-Mtb-specific cells do not respond to antigen, therefore,
no priming occurs in any of these cell populations in LNs and no precursor cells are generated.
We assume that neither effector nor effector memory cells re-enter the LN after migrating into
blood: they recirculate through blood and eventually migrate to lung (as shown in Fig 2B). The
production of non-Mtb-specific effector cells was captured as a source term in blood and was
calibrated to the T cell dataset prior to infection (S5 Table).
Computation information
GranSim is an agent-based model implemented using the C++ programming language in con-
junction with Boost libraries (distributed under the Boost Software License–available at www.
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boost.org). The graphical user interface (GUI) was built using the Qt framework (open-source,
distributed under GPL–available at qt.digia.com), which allows us to display, track and plot dif-
ferent readouts of the in silico granuloma simulation in real-time. The lymph node and blood
compartments are modeled together as an ordinary differential equation (ODE) system (as
shown in Fig 2B). They are interfaced with GranSim by numerical ODE solvers implemented
as part of the C++ platform all within our own code. The three-compartmental model can be
used with or without GUI visualization and is cross-platform (Mac, Linux, Windows). Compu-
tational model simulations were performed on XSEDE’s OSG Condor pool and NERSC’s Edi-
son Cray XC30. Initial ODE model calibration and analysis of the results were performed in
Matlab, as well as all post-processing analysis of data generated by our in silicomodel. We use
the min-max range NHP pre-infection data from the T cell dataset to establish ranges for the
initial conditions for the blood ODE model (homeostasis, see S8 Table for details on the initial
conditions). We assume that these levels represent a flow of cells constantly trafficking through
LNs. Therefore, initial numbers of cells in the lung draining LN were calculated by dividing the
number of those in the blood, by the number of LNs in the host (i.e., parameter host_Ln in S9
Table). We also assumed a frequency of Mtb-specific Naïve T cells (parameter λ) between
0.001 and 0.00001 (i.e., [1e-3, 1e-5]) [62].
Most model parameter values used herein are taken from our previously published studies
[28,29,30,31,53,63,64] and are listed in S9 Table. Additionally, we rely on uncertainty analysis
techniques to efficiently explore the parameter space and inform on baseline behaviors of the
system (uncertainty analysis—UA). Here we used Latin Hypercube Sampling (LHS, reviewed
in [65]) for UA. The LHS algorithm is a stratified Monte Carlo sampling method without
replacement [65]. It was used to generate 1,000 unique parameter sets, which are simulated in
replication 10 times (a total of 10,000 in silico simulations). We varied 21 parameters/mecha-
nisms in blood and LN compartments, as well as 8 initial conditions for Naïve, Effector, Effec-
tor Memory and Effector Memory CD4+ and CD8+ (see S8 and S9 Tables for the ranges used
to generate the in silico granulomas and blood/LN dynamics). Parameters/mechanisms in
GranSim have been updated to reflect latest knowledge and data (see [30] for details and http://
malthus.micro.med.umich.edu/GranSim/) and were held fixed in our LHS experiments as
blood and LN parameters were varied.
The in silico dataset analysis
The in silico dataset comprises sets of 10,000 model simulations (i.e., 1,000 x 10 replications) of
single granulomas coupled to LN and blood dynamics over a time span of 600 days post infec-
tion (step 3 in Fig 1). We analyzed the following readouts across the three compartments:
blood compartment (16 variables), lymph node (15 variables), macrophage and T cell counts
in the lung, as well as measures in the lung such as lesion size, TNF and IL-10 total levels, cyto-
toxic killing, and infected macrophage bursting rate (total of 48, see S11 Table for the complete
list). We used the same time points from the experimental data (e.g., 9 time points from the T
cell dataset, days 10, 20, 30, 42, 56, 90, 120, 150 and 180 post infection) and computational
model simulations for direct comparison between the in vivo and in silicomodel outputs for
the blood measures (step 2 in Fig 1). We extended the analysis up to 600 days to perform the
scaling-to-host step, since we matched to NHPs that have been necropsied between 200 and
600 days post infection. Principal component analyses (PCA) were performed on the in silico
dataset (step 4 in Fig 1), after the computational model was calibrated to the experimental data.
We defined Mtb-specific frequencies for each T cell phenotype as the ratio between the number
of Mtb-specific T cells over the total number of T cells.
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Model calibration
The computational model was calibrated with respect to i) CFU/granuloma dynamics, based
on our recent NHP experimental data [21,22] (see S1 Table and step 2 in Fig 1), and on ii)
blood T cell dynamics as measured in the T cell dataset (see S5 Table and step 2 in Fig 1). S8
and S9 Tables shows the ranges used to generate our in silico dataset of 10,000 granulomas
(step 3 in Fig 1). The 10,000 model simulations returned CFU dynamics as well as T cell
dynamics in the blood that we compare to the NHP experimental data (as shown in Figs 3 and
4). Since the T cell datasetmeasured total T cell populations rather than Mtb-specific subsets,
we summed Mtb-specific and non Mtb-specific in silico cell predictions to match our experi-
mental data. Due to the large variability in the T cell dataset, we did not superimpose strict cri-
teria for model calibration. The computational model was considered to be adequately
calibrated if minimum, mean, median and maximum in silico trajectories were within the lon-
gitudinal data measured in the experimental settings.
Only 12 NHPs (of the 28 in the datasets used for classification) have both blood and lung
data available, so we used these 12 NHPs for the initial model calibration (Fig 4). We then
merged both the lung data on CFU of the 43 NHPs with the blood data of the 12 NHPs to see if
all the virtual NHPs have blood dynamics within the experimental ranges (Fig 4). The 12
NHPs are biased towards latent (9) vs active TB (3) and limited to 6 months (while the lung
experimental data are available up to 600 days). Fig 5 has the T cell Memory phenotype data
shown as frequencies of T cell producing any cytokine in response to ESAT6/CFP10
stimulation.
For the reasons outlined above and since time courses of NHP blood experimental data are
not available to match our Mtb-specific T cell frequencies predictions (step 6 in Fig 1), Figs 7,
S8 and S9 only show in silico time courses.
Building virtual NHPs for scaling-to-host in silico biomarker predictions
To allow our model to be directly comparable to NHP and human data that track infection
progression, we developed a method to scale single granuloma outcomes in lungs to host level
readouts in blood. The virtual NHP generation approach uses a different set of NHP data com-
pared to the machine learning approach (step 5 in Fig 1). We guide the generation of virtual
NHPs by replicating granuloma heterogeneity and variability in the lung up to 600 days post
infection (i.e., # of granuloams and CFU/granuloma in S1 Table). We then analyze the in silico
blood dynamics to make predictions on potential biomarkers for infection outcome. The com-
plete protocol, illustrated in Fig 6, comprises the following steps: i) select the number of granu-
lomas to replicate upon infection over time in each known NHP from our NHP experimental
data (see S1 Table), ii) mimic CFU/granuloma values by sampling only granulomas that have
similar CFU burden from our repository of 10,000 in silico granulomas (based on Figs 3 and 4,
the computational model readouts are within the range of variability measured by experimental
data in the lung and in the blood, thus the sampling is warranted), iii) collect in silico blood
readouts predicted for each granuloma, and then average them across all granulomas, iv) repeat
steps ii) and iii) K times (to capture within host variability, we used K = 1,000) and generate
statistics (e.g., means, medians, standard deviations) on the K replications to recapitulate in sil-
ico blood data on the single virtual host, v) repeat steps i)-iv) for all the NHPs in the dataset.
For example, NHP 21710 (latent TB, row 14 in S1 Table) has 12 granulomas; 8 of them are
sterile and 4 have the following CFU burdens: 38, 142, 38 and 1133. Virtual NHP 21710 was
built by sampling 12 in silico granulomas from our repository at the day NHP 21710 was nec-
ropsied (i.e., 370 days post infection). For sterile granulomas, we use the criteria of CFU<1 per
granuloma, and for the non-sterile granulomas we sample from subsets of in silico granulomas
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that fell within a ±α range of the NHP experimental data (Fig 6). We used α = 10%. Numbers
of in silico granulomas that satisfy our condition for sterile granulomas (i.e. CFU<1) at day
370 post infection is 2257 out of 10,000. For the first non-sterile granuloma of NHP 21710
(CFU = 38), we first select in silico granulomas with CFU in the ±10% range, namely [30,46]
(i.e., 66 granulomas), and then randomly choose one without replacement (thus the third gran-
uloma, which has the same CFU, will not be assigned to the in silico granuloma selected for the
first one). The second granuloma will be selected from the range [113,170] (i.e., 12 granulo-
mas), and so on. Once all the in silico granulomas have been sampled, we average the blood
readouts across all the simulated granulomas (12 granulomas for NHP 21710) and then com-
pute the values for total T cell levels as well as for the Mtb-specific T cell frequencies in the
blood. We repeat the same procedure K times (K = 1000) for the same virtual NHP to account
for granuloma outcome variability and generate statistics (mean, median, standard deviations)
for the variables used to correlate in silico blood time courses to infection outcome (e.g., total T
cell levels as well as Mtb-specific T cell frequencies, see Fig 6 for details).
We applied the scaling to host method to 43 NHPs that have been classified as either latent
(20 NHPs) or active (23 NHPs) TB, and that have data on numbers of granulomas in lung and
CFU/granuloma for each granuloma (highlighted in yellow in S1 Table). Once all the blood
readout statistics have been computed on the 43 virtual NHPs, we generated trajectories (see
Figs 7, S8 and S9) by grouping active vs latent virtual NHPs and we test if any of them are sig-
nificantly different (t-test) over time and likely predictive of infection outcome (step 6 in Fig
1). Figs 7, S8 and S9 show how we used in silico predictions for the time courses of total CD4
+ and CD8+ T cell levels, as well as Mtb-specific T cell frequencies to predict the virtual NHPs
infection outcome, using the clinical known classification between latent and active TB groups
from S1 Table.
Supporting Information
S1 Text. Supplementary Materials and Methods.Mathematical Model describing cell popula-
tion dynamics in the blood and lymph node compartments of the computational model
described in Fig 2B.
(DOCX)
S2 Text. Supplementary Materials and Methods. T cell recruitment and T cell proliferation in
the lung.
(DOCX)
S1 Fig. Representative flow cytometry plots. (2712- 6months post infection-stimulated with
ESAT-6 (A-D) or P&I (E)) outlining gating strategies employed in the analysis T cells in
PBMC. (A) Singlets were gated based on Forward scatter height (FSC-H) and area (FSC-A).
From the singlets, (B) Lymphocytes were selected based on SSC and FSC (i.e., size and granu-
larity). CD4 or CD8 T cells (C) were gated on the lymphocyte population. From either CD4 or
CD8 T cells memory subsets (D) were selected based on CD45RA and CD27 markers as fol-
lows: CD45RA+CD27+ as Naïve, CD45RA-CD27+ as Central memory, CD45RA-CD27- as
Effector memory and CD45RA+CD27- as Effector or terminally differentiated. Cytokine pro-
ducing CD4 or CD8 T cells or memory subsets were gated as shown (E). Arrow indicates
sequence of gating.
(TIF)
S2 Fig. ROC, sensitivity and specificity of the results of supervised classification algorithms
applied to the blood data of the 28 NHPs. The performances of the binary classification algo-
rithms shown in Table 2 have been measured on the single and memory cytokine datasets by
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calculating their receiving operating characteristic (ROC) curves (Panels A and B). The area
under the curve (AUC) and misclassification error values ere shown in Panels C and D. The
script to generate the ROCs have been written in R, using the library “ROCR” and the perfor-
mance function with true (i.e., tpr) and false positive rates (i.e., fpr) arguments for the cost
function (e.g., performance(pred,"tpr","fpr")). The cost associated with tpr and fpr is the same.
(TIF)
S3 Fig. Biomarker discovery on the in silico data. (A-C): Principal Component Analysis
(PCA) performed only on Mtb-specific variables in the blood compartment from the same
repository of 10,000 in silico granuloma simulations used to generate Fig 4. (A): Pareto plot of
the top 10 PCAs. We can reach ~70% of explained variance by summing the top 2 PCAs. Panel
B: scatterplot of PCA1 and PCA2. Panel C: biplot associated to Panel B, with categories listed
on the four quadrants. Each category is listed as Mtb-specific T cell phenotype at a certain time
point post infection. For example “E8 42” refers to Effector CD8+ T cells at day 42 post infec-
tion. (Other T cell phenotypes shown: CM [central memory]).
(TIF)
S4 Fig. Principal Component Analysis (PCA) applied to the in silico data generated by the
3-compartmental model. Blood and Lung readouts (49 readouts total). (A)-(C): scatter plots
of the 1st principal component versus the 2nd, 3rd and 4th principal component, respectively.
(D)-(E): scatter plots of the 2nd principal components versus the 3rd and 4th principal compo-
nents. (F): scatter plot of the 3rd and 4th principal components.
(TIF)
S5 Fig. Biplots associated to S3 Fig. See S11 Table for details on the labels of the scores. The
number after the underscore sign refer to the day after infection on which that variable as been
measured. We plot the top 4 principal components because they explain ~60 of the variability.
(A)-(C): biplots of the scores associated with the scatter plots of the 1st principal component
versus the 2nd, 3rd and 4th principal component (as shown in S4 Fig, panels (A)-(C)), respec-
tively. (D)-(E): biplots of the scores associated with the scatter plots of the 2nd principal compo-
nents versus the 3rd and 4th principal components (as shown in S4 Fig, panels (D)-(E)). (F):
biplot of the scores associated with the scatter plot of the 3rd and 4th principal components (as
shown in S4 Fig, panel (F)).
(TIF)
S6 Fig. Biomarker discovery on the in silico data. Each panel shows the same repository of
10,000 in silico granuloma simulations coupled to the blood and LN dynamics used to generate
Figs 3 and 4. Each point on the plots represents one in silico granuloma. Here we couple infor-
mation from both the blood (x-axis) and the lung (y-axis). The y-axis represents CFU/granu-
loma, while the x-axis is the ratio of Mtb-specific vs non Mtb-specific Effector CD4+ cell levels
in the blood at day 167 post infection. Both axis are displayed on a log scale. Panels B and F are
used in S7 Fig (panels C and D) for detailed studies. (A)-(D): scatter plots of CFU per granu-
loma (y-axis) versus Mtb-specific frequencies of different CD4+ T cell phenotypes (i.e., Naïve,
Effector, Central Memory and Effector Memory). (E)-(H): scatter plots of CFU per granuloma
(y-axis) versus Mtb-specific frequencies of different CD8+ T cell phenotypes (i.e., Naïve, Effec-
tor, Central Memory and Effector Memory).
(TIF)
S7 Fig. Biomarker discovery on the in silico data. (A-D): Scatter plots of the same repository
of 10,000 in silico granuloma simulations coupled to the blood and LN dynamics used to gener-
ate Figs 3 and 4. Each point on the plots represents one in silico granuloma. Here we couple
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information from both the blood (x-axis) and the lung (y-axis). The y-axis represents CFU/
granuloma, while the x-axis is the Mtb-specific frequency of Effector CD4+ (A—day 140 / C—
day 167) and CD8+ (B—day 140 / D—day 167) cell levels in the blood (A—day 140 / B—day
167). Mtb-specific frequency is calculated by dividing the number of Mtb-specific cells over the
total T cells, within each specific phenotype. So, for example the values on the x axis of Panel D
are calculated by dividing Mtb-specific Effector CD4+ T cell counts by the total Effector CD4
+ T cell counts. Both axis are displayed on a log scale. The horizontal black lines are located at
100 CFU per granuloma and they separate granuloma clusters emerging from the 10,000 in sil-
ico simulations as either low or high CFU granulomas. Vertical red lines are the Mtb-specific
frequency thresholds suggested in each panel to predict granuloma with low versus high CFU.
We chose these two time points (i.e., day 140 and day 167) as they displayed the best separation
between granuloma clusters with low versus high CFU burden. All other Mtb-specific frequen-
cies that can be calculated on the in silico data (namely, naïve, effector, central and effector
memory ratios for CD4+ and CD8+ T cells) and plotted against CFU/granuloma at the latest
time point measured in the memory dataset (i.e., day 167 post infection) are shown in S6 Fig.
There is a small number of granulomas that do not fall into either these groups, (i.e., where
high CFU is associated with low Mtb-specific T cell frequencies, false positive group if we use
the frequency threshold as a biomarker).
(TIF)
S8 Fig. Scaling to host infection outcome predictions–Total T cells and frequencies. Trajec-
tories over 600 days of T cell levels, both total and Mtb-specific, as well as Mtb-specific T cell
frequencies. The data shown have been generated following steps illustrated in Fig 6, as well as
in the Materials and Methods section. The 43 virtual NHPs have been classified based on
known clinical outcome and are displayed in all the panels as mean +/- 2x(standard error). The
asterisks show significant (p<0.05) student t-test between the two trajectories at the same time
point. Panel A: Total T cell levels. Panel B: Total CD4+ T cell levels. Panel B: Total Mtb-specific
T cell levels. Panel C: Total non Mtb-specific T cell levels. Panel D: Total non Mtb-specific CD4
+ T cell levels. Panel E: Total non Mtb-specific CD8+ T cell levels. Panel F: Frequency of Mtb-
specific Naïve CD4+ T cells. Panel G: Frequency of Mtb-specific Central Memory CD4+ T
cells. Panel H: Frequency of Mtb-specific Naïve CD8+ T cells. Panel I: Frequency of Mtb-spe-
cific Central Memory CD8+ T cells.
(TIF)
S9 Fig. Scaling to host infection outcome predictions–Ratios of Mtb-specific CD4+ T cell
phenotypes. Trajectories over 600 days of ratios of Mtb-specific CD4+ T cell levels. The data
shown have been generated following steps illustrated in of 6, as well as in the Materials and
Methods section. The 43 virtual NHPs have been classified based on known clinical outcome
and are displayed in all the panels as mean +/- 2x(standard error). The asterisks show signifi-
cant (p<0.05) student t-test between the two trajectories at the same time point. Panel A: Ratio
of Effector Memory over Central Memory Mtb-specific CD4+ T cells. Panel B: Ratio of Effector
over Central Memory Mtb-specific CD4+ T cells.
(TIF)
S1 Table. Non-human primate data on infection outcome classification, number of granu-
lomas and CFU/granuloma.
(XLS)
S2 Table. Single cytokine dataset (blood).
(XLSX)
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S3 Table. Multiple cytokine dataset (blood).
(XLS)
S4 Table. Memory single cytokines dataset (blood).
(XLSX)
S5 Table. T cell dataset (blood).
(XLS)
S6 Table. ESAT6-CFP10 memory T cell dataset (blood).
(XLS)
S7 Table. Unsupervised classification algorithms results.
(PDF)
S8 Table. Parameter values and ranges for the initial conditions of the computational
model.
(PDF)
S9 Table. All other parameter values and ranges of the computational model.
(PDF)
S10 Table. Statistics of S6 Fig.
(DOC)
S11 Table. List of in silico data readouts.
(PDF)
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